Navigation Links
Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

After treating 200 late stage cancer patients since 2007 with strong safety and efficacy results, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate. "This is the first step to turn our Advanced Therapy Access Program results into cancer therapeutics", says Pekka Simula, CEO and co-founder.

"The results have been strong for late stage solid tumor cancers where routine therapies have failed.Time is critical in the treatment of cancer. We are confident that when treating earlier stage patients, our oncolytic virus therapy will prove even more significant", says Research Professor Akseli Hemminki, CSO and co-founder, and a research group leader at the University of Helsinki.

"Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, combines very promising results in humans with strong science", comments Dr Johan Christenson, partner with HealthCap.


Contact: Timo Ahopelto
University of Helsinki

Page: 1

Related medicine news :

1. Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference
2. Study says therapeutics for trauma patients may not be effective due to an infection
3. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
4. Northwest Biotherapeutics Inc. Appoints Market Media Connect as Communications Agency of Record
5. Echo Therapeutics Provides Business Update
6. Reportlinker Adds The Future of Respiratory Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
7. Reportlinker Adds The Future of Cardiovascular Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
8. Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
9. Anesiva Stockholders Approved Merger With Arcion Therapeutics but Merger Remains Contingent on Other Closing Conditions
10. Osseon Therapeutics, Inc. Announces it has Received Canadian Medical Device Licenses From Health Canada
11. Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology: